At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer
In Brief
A Phase 1 clinical trial evaluating S-1 for Gastrointestinal Neoplasms and Gastric Cancer. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to determine maximum tolerated dose (MTD), dose limiting toxicities (DLT) and recommend a proper dose for our phase II study of S-1 when combined with radiation therapy for locally advanced or recurrent gastric cancer.
Study Details
Timeline
Interventions
S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.